Malta’s fastest-growing science company has announced a new partnership which will benefit thousands of cancer patients in the long run.
Evolve has teamed up with Swiss precision-medicine company Saphetor to become an official partner of VarSome Clinical, a clinically certified platform for interpretation of Next-Generation DNA Sequencing data.
The agreement extends Evolve’s portfolio of services for its customers and will ultimately help doctors, hospital consultants and medical specialists give faster and more accurate results for the benefit of patients.
Evolve managing director Christopher Busuttil Delbridge said: ‘This new partnership helps us to deliver high-quality, state-of-the-art bioinformatics services in the clinical and research fields, along with our wide portfolio of testing procedures for cancer genetics.
‘Having been the ones to introduce Next-Generation DNA Sequencing to Malta, Evolve is best positioned to continue building on its knowledge and services to further scientific advancement in this sector.’
Saphetor founder Andreas Massouras added: ‘We are excited to count Evolve among our distributors for our bioinformatics tools, and we are prepared to work closely with their team to provide their clients with an integrated solution for diagnostics purposes.’
Saphetor is the creator of VarSome, a suite of intuitive and data-driven bioinformatics solutions both for clinicians and researchers.
The VarSome.com search engine and professional community is freely accessible, featuring a widely-recognized community-driven knowledge base that enables flexible queries across more than 30 genetic and genomic data resources.
VarSome Pro and VarSome Clinical are professional editions of VarSome with powerful functionality and sophisticated analysis tools to help doctors deliver faster and more accurate diagnoses and treatments for genetic conditions.